Bringing the fundamentals into focus…
Back to Lyell Immunopharma, Inc.
How Lyell Immunopharma, Inc. stacks up
LYEL · against 454 other Healthcare companies listed in US-listed
Growth
5/ 100
Near the bottom of its peers.
Ranked #423 of 455 · scores higher than 6% of peers
Bars: peers in each 10-point band of the growth score44 peers with a growth score of 0–9, including LYEL · Click a bar to see the companies
Why growth scores 5?
Weighted metrics compared with all Healthcare companies.Mainly because of its 3-year revenue growth and revenue growth, which are weaker than most Healthcare peers.
- slower revenue growth over three years: weaker than 100% of peers. 3-year revenue growth: -91.8% vs peer median 5.8%
- slower revenue growth over the last year: weaker than 96% of peers. Revenue growth: -55.0% vs peer median 6.1%
- Still loss-making, but the loss per share narrowed. Earnings per share growth: — vs peer median 9.8%
Metric by metric
Position: dot = LYEL, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | LYEL | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 475 reported | -55.0% | 11.0% | 8% | 33% | |
| Earnings per share growthHigher is better · 171 reported | Not reported | 21.2% | — | — | 33% |
| 3-year revenue growthHigher is better · 433 reported | -91.8% | 11.0% | 0% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around LYEL| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 460M USD | 100 | 53 | |
| 2 | 1.4B USD | 99 | 73 | |
| 2 | 441M USD | 99 | 81 | |
| 2 | 9.5B USD | 99 | 31 | |
| 2 | 87M USD | 99 | 27 | |
| 423 | 542M USD | 5 | 20 | |
| 423 | 5.0B USD | 5 | 27 | |
| 423 | 4.8B USD | 5 | 29 | |
| 423 | 914M USD | 5 | 3 | |
| 423 | 378M USD | 5 | 24 | |
| 423 | 103.2B USD | 5 | 18 | |
| 423 | 27.6B USD | 5 | 28 | |
| 431 | 303M USD | 4 | 44 | |
| 431 | 8.0B USD | 4 | 30 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score